IGFBP2 Antibodies

Structure of IGFBP2

IGFBP2 is a secreted glycoprotein with a molecular weight of approximately 31 kDa. There are differences in length and glycosylation sites among different species.

IGFBP2 consists of 289 amino acids and is composed of three parts: the N-terminal conserved region, the linker region, and the C-terminal domain. Both the N-terminal and C-terminal regions are rich in cysteines and form multiple intramolecular disulfide bonds, jointly forming a highly specific IGF binding interface. The linker region is prone to proteolysis, resulting in functional fragments with independent activity. The N-terminal domain contains a characteristic GCGCCxxC motif, which is a hallmark of the IGFBP family; the thyroglobulin type-1 repeat sequence in the C-terminal domain is involved in non-IGF-dependent regulatory processes such as cell surface adhesion.

Fig. 1 Structure and domains of IGFBP-2.¹

Key structural properties of IGFBP2:

• The N-terminal and C-terminal are highly conserved, each containing 12 to 14 cysteines
• Intra-chain disulfide bonds stabilize the 3D conformation and form the IGF high-affinity binding interface
• Central connection area for unstructured area, vulnerable to protease shear

Functions of IGFBP2

The main function of IGFBP2 is to regulate the bioavailability of insulin-like growth factors. It also participates in various non-IGF-dependent physiological processes, such as cell migration, adhesion and metabolic regulation.

IGFBP2 possesses both IGF-dependent and IGF-independent regulatory mechanisms. Its functional switching mainly relies on the proteolytic cleavage of the linker region and changes in the cellular microenvironment.

Applications of IGFBP2 and IGFBP2 Antibody in Literature

1. Khan, Shumsuzzaman. "IGFBP-2 signaling in the brain: from brain development to higher order brain functions." Frontiers in Endocrinology 10 (2019): 822. https://doi.org/10.3389/fendo.2019.00822

The article indicates that IGFBP-2 is the most abundant neuro-regulatory polypeptide in cerebrospinal fluid, and is highly expressed in brain regions such as the hippocampus during brain development and in adulthood. It regulates neural plasticity through pathways that depend on or are independent of IGF receptors, and participates in advanced cognitive functions such as learning and memory. It is a neurotrophic factor throughout the entire life cycle.

2. Chen, Xiu, et al. "IGFBP2 drives epithelial-mesenchymal transition in hepatocellular carcinoma via activating the Wnt/β-catenin pathway." Infectious Agents and Cancer 18.1 (2023): 73. https://doi.org/10.1186/s13027-023-00543-6

The article indicates that insulin-like growth factor binding protein 2 (IGFBP2) is highly expressed in liver cancer. It promotes epithelial-mesenchymal transition (EMT) and tumor metastasis by activating the Wnt/β-catenin signaling pathway. Knockdown of this protein can reverse the expression of related proteins.

3. Alicea, Gretchen M., et al. "Age-related increases in IGFBP2 increase melanoma cell invasion and lipid synthesis." Cancer Research Communications 4.8 (2024): 1908-1918. https://doi.org/10.1158/2767-9764.CRC-23-0176

The article indicates that the skin fibroblasts of the elderly secrete high levels of IGFBP2. This secretion activates the PI3K pathway, promoting the fatty acid synthesis of melanoma cells, thereby enhancing their invasiveness and metastasis. Neutralizing IGFBP2 can inhibit tumor growth.

4. Li, Hui, et al. "IGFBP2 function as a novel biomarker for active lupus nephritis." Journal of Molecular Medicine 100.10 (2022): 1479-1491. https://doi.org/10.1007/s00109-022-02241-z

The article indicates that IGFBP2 is significantly elevated in patients with active lupus nephritis and can serve as a highly specific diagnostic marker. Neutralizing IGFBP2 can inhibit T cell activation, increase the proportion of regulatory T cells, and significantly improve mouse nephritis by inhibiting the AKT/mTOR pathway.

5. Lu, Hengxiao, et al. "IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer." Cell Death & Disease 15.6 (2024): 447. https://doi.org/10.1038/s41419-024-06843-y

The article indicates that IGFBP2 is highly expressed in patients with non-small cell lung cancer who are resistant to gefitinib. It upregulates CXCL1 by activating STAT3 and collaborates with ITGA5 to promote the survival of cancer cells in the drug environment, making it a potential biomarker of resistance and an intervention target.

Company A: IGFBP2 Antibodies for Research

Company A specializes in the production of high-quality IGFBP2 antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom IGFBP2 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our IGFBP2 antibodies, custom preparations, or technical support, contact us at email.